1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)
    Meeting Abstract

    Feldman, D. R.; Feuilly, M.; Meng, J.; Lister, J.; Marteau, F.; Morris, M. J.; George, D. J.; Choueiri, T. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial
    Meeting Abstract

    Felip, E.; Horn, L.; Patel, J. D.; Sakai, H.; Scheele, J.; Bruns, R.; Paik, P. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
    Meeting Abstract

    Felip, E.; Hellmann, M. D.; Hui, R.; Carcereny, E.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC)
    Meeting Abstract

    Dos Santos Fernandes, G.; Chatila, W. K.; Yaeger, R.; Mendelsohn, R. B.; Stadler, Z. K.; Segal, N. H.; Varghese, A. M.; Lagunes, D. R.; Diaz, L. A.; Shia, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Rini, B. I.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S)
    Meeting Abstract

    El Dika, I. H.; Capanu, M.; Chou, J. F.; Harding, J. J.; Hrabovsky, A. D.; Do, R. K. G.; Shia, J.; Germino, J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)
    Meeting Abstract

    Drilon, A. E.; Ou, S. H. I.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V. W.; Kim, H.; Kim, T. M.; Ahn, M. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Doebele, R. C.; Riely, G. J.; Spira, A. I.; Horn, L.; Piotrowska, Z.; Costa, D. B.; Neal, J. W.; Zhang, S.; Reichmann, W.; Kerstein, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC)
    Meeting Abstract

    Das, R. K.; Furchtgott, L.; Meyerhardt, J. A.; Nixon, A. B.; Innocenti, F.; Cunha, D.; Rich, K.; Lenz, H. J.; Niedzwiecki, D.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save